FindTrial
Sign In

Novel Radiomics signature on MRI before and after neoadjuvant chemotherapy in breast cancer to predict axillary lymph node metastasis and prognosis: A machine-learning-analysis based ambispective cohort Study (RBC-02)

Novel Radiomics signature on MRI before and after neoadjuvant chemotherapy in breast cancer to predict axillary lymph node metastasis and prognosis: A machine-learning-analysis based ambispective cohort Study (RBC-02)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024113
Enrollment
Unknown
Registered
2019-06-26
Start date
2019-06-26
Completion date
Unknown
Last updated
2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:Clinical outcome
Index test:Deep&#32
Learning&#32
Algorithms&#32
prediction&#32
model

Sponsors

Sun Yat-Sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Female aged from 18 to 75 years; 2. Primary lesion diagnosed as invasive breast cancer from January 2011 to December 2018; 3. Imaging examination confirmed no distant organ metastasis; 4. Received neoadjuvant chemotherapy for drugs such as taxanes, anthracyclines, and platinum as planned; 5. Completed breast MRI examination before or after neoadjuvant chemotherapy; 6. Accepted breast cancer surgery and axillary lymph node dissection; 7. ECOG-PS 0-2.

Exclusion criteria

Exclusion criteria: 1. Accompanied with other primary malignant tumors; 2. Inflammatory breast cancer; 3. Bilateral breast cancer; 4. Malignant tumor history in 5 years; 5. Patients with cervical or contralateral axillary lymph node metastasis; 6. Incomplete imaging or medical history data.

Design outcomes

Primary

MeasureTime frame
Axillary lymph node metastasis;SEN, SPE, ACC, AUC of ROC;—

Secondary

MeasureTime frame
pathologic Complete Response, pCR;Overall Survival, OS;Diseas-free Survival, DFS;—

Countries

China

Contacts

Public ContactHerui Yao

Sun Yat-Sen Memorial Hospital, Sun Yat-sen University

yaoherui@mail.sysu.edu.cn+86 13500018020

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026